相似文献
1
Development of (166)Ho-phytate Complex for Radiosynovectomy.
Nucl Med Mol Imaging. 2011 Jun;45(2):87-92. doi: 10.1007/s13139-010-0048-6. Epub 2011 Feb 17.
2
Preparation and evaluation of Lu-(177) phytate Complex for Radiosynovectomy.
World J Nucl Med. 2014 Jan;13(1):22-7. doi: 10.4103/1450-1147.138570.
3
Development of (177)Lu-phytate Complex for Radiosynovectomy.
Iran J Basic Med Sci. 2013 May;16(5):705-9.
4
Production, quality control and pharmacokinetic studies of Ho-EDTMP for therapeutic applications.
Sci Pharm. 2010 Jul-Sep;78(3):423-33. doi: 10.3797/scipharm.1004-21. Epub 2010 Jun 9.
5
Development of (166)Holmium-1,2 Propylene Di-amino Tetra (Methy1enephosphonicacid) as a Possible Bone Palliation Agent.
World J Nucl Med. 2014 Jan;13(1):28-33. doi: 10.4103/1450-1147.138571.
6
Production, Quality Control and Biological Evaluation of (166)Ho-PDTMP as a Possible Bone Palliation Agent.
Iran J Basic Med Sci. 2013 May;16(5):719-25.
7
Preparation and bioevaluation of 166Ho labelled hydroxyapatite (HA) particles for radiosynovectomy.
Nucl Med Biol. 2002 Feb;29(2):199-209. doi: 10.1016/s0969-8051(01)00303-1.
8
Preparation and quality control of ¹⁷⁷Lu-[tris(1,10-phenanthroline) lutetium(III)] complex for therapy.
Nucl Med Rev Cent East Eur. 2010;13(2):49-54.
9
Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer.
Nucl Med Commun. 2009 May;30(5):362-7. doi: 10.1097/MNM.0b013e328329981a.
10
Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer.
J Nucl Med. 2013 Jan;54(1):111-6. doi: 10.2967/jnumed.112.106609. Epub 2012 Oct 25.
本文引用的文献
1
Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer.
Nucl Med Commun. 2009 May;30(5):362-7. doi: 10.1097/MNM.0b013e328329981a.
2
Preparation of Holmium-166 Labelled Macroaggregates for radionuclide synovectomy.
Nucl Med Rev Cent East Eur. 2003;6(1):1-4.
3
Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.
Cancer Biother Radiopharm. 2003 Apr;18(2):225-30. doi: 10.1089/108497803765036391.
4
Potential 166Ho radiopharmaceuticals for endovascular radionuclide therapy. II. Preparation and evaluation of 166Ho-DTPA.
Nucl Med Commun. 2001 Jan;22(1):97-103. doi: 10.1097/00006231-200101000-00014.
5
Treatment of Bowen's disease with a specially designed radioactive skin patch.
Eur J Nucl Med. 2000 Jul;27(7):842-6. doi: 10.1007/s002590000262.
6
Biodistribution and kinetics of holmium-166-chitosan complex (DW-166HC) in rats and mice.
J Nucl Med. 1998 Dec;39(12):2161-6.
Zotero 插件